Zhejiang Cancer Hospital: Nasopharyngeal Carcinoma trials

The registry lists 25 Nasopharyngeal Carcinoma studies with Zhejiang Cancer Hospital as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 2 14Phase 3 4Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPCNot yet recruitingNCT06752382Phase 2
• Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal CarcinomaNot yet recruitingNCT06364826Phase 2
• SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPCRecruitingNCT05652192Phase 2
• Radiotherapy Combined With Endostatin and Capecitabine for NPCRecruitingNCT05514275Phase 2
• Immune Score Based Radiomics in Nasopharyngeal CarcinomaRecruitingNCT05126160
• PET/MR in Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT03657017Not applicable
• Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic LesionsRecruitingNCT03129412Phase 2
• Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06055816Phase 2
• Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT05813626Phase 2
• Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal CarcinomaStatus unknownNCT05232552Phase 2
• Tegio Consolidation Therapy for NPC Patients With High Risk of MetastasisStatus unknownNCT03904225Phase 2
• Interleukin-11 Can Prevent and Treat of Radioactive Oral MucitisStatus unknownNCT03720340Phase 3
• Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined ChemotherapyStatus unknownNCT03647527
• TOMO Versus IMRT in Nasopharyngeal Carcinoma PatientsStatus unknownNCT03588403
• Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma PatientsStatus unknownNCT03411954
• Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)Status unknownNCT03213587Phase 2
• Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03058432Phase 2
• Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal CarcinomaCompletedNCT03025958Phase 2
• Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal CarcinomaStatus unknownNCT03015727Phase 3
• A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma PatientsStatus unknownNCT02948699Phase 4
• Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal CarcinomaStatus unknownNCT02945878
• A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.Status unknownNCT02878889Phase 2
• Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT01915134Phase 3
• Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal CarcinomaStatus unknownNCT01612286Phase 2
• Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal CarcinomaStatus unknownNCT01536223Phase 3